{ "id": "epm1cz4a65", "slug": "carboplatin-paclitaxel-and-nivolumab-regimen", "title": "Carboplatin, paclitaxel, and nivolumab regimen", "updated": "2026-09-30", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines" }, { "id": "life.health.medicines.cancer-chemotherapy", "label": "Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy" }, { "id": "life.health.medicines.cancer-chemotherapy.immunotherapy-and-immunochemotherapy", "label": "Immunotherapy and immunochemotherapy", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy.immunotherapy-and-immunochemotherapy" } ], "geo": [ { "id": "geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy", "label": "Non-geographic · 2001 to 2020: Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t2001", "label": "Non-geographic · 2001 to 2020", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001" }, { "id": "geo.nongeo.t2001.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life" }, { "id": "geo.nongeo.t2001.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health" }, { "id": "geo.nongeo.t2001.life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.medicines" }, { "id": "geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy", "label": "Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.medicines.cancer-chemotherapy" } ] } ], "excerpt": "The carboplatin, paclitaxel, and nivolumab regimen combines two chemotherapy drugs with the checkpoint inhibitor nivolumab, given intravenously, and is best established as neoadjuvant treatment of resectable non-small cell lung cancer.", "snippet": "The carboplatin, paclitaxel, and nivolumab regimen combines two chemotherapy drugs with the checkpoint inhibitor nivolumab, given intravenously, and is best established as neoadjuvant treatment of resectable non-small cell lung cancer.", "node": "life.health.medicines.cancer-chemotherapy.immunotherapy-and-immunochemotherapy", "markdown": "# Carboplatin, paclitaxel, and nivolumab regimen\n\nThe carboplatin, paclitaxel, and nivolumab regimen is a combination of two cytotoxic chemotherapy drugs with the PD-1 checkpoint inhibitor nivolumab, given intravenously. Its best-established use is neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) before surgery, based on the CheckMate 816 trial.[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) A closely related quadruplet, adding bevacizumab, was tested first-line in metastatic nonsquamous NSCLC in the TASUKI-52 trial[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501244/) • [3](https://pubmed.ncbi.nlm.nih.gov/34139272/), and a further variant adds ipilimumab for metastatic disease in the CheckMate 9LA framework.[4](https://www.eviq.org.au/getmedia/798f6494-62d4-4651-af0a-62a00f167d1d/ID-3955-Non-small-cell-cancer-metastatic-cARBOplatin-paclitaxel-ipilimumab-and-nivolumab-protocol-and-PI.pdf.aspx)\n\n| Key fact | Detail |\n|---|---|\n| Neoadjuvant dosing (CheckMate 816) | Nivolumab 360 mg, paclitaxel 200 mg/m², carboplatin AUC 6, all IV on day 1 of each 21-day cycle, up to 3 cycles before surgery[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) |\n| Neoadjuvant indication | Resectable stage IIA–IIIB (TNM 8th edition) squamous or nonsquamous NSCLC without targetable EGFR or ALK alterations, ECOG 0–1[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) |\n| CheckMate 816 efficacy | Median event-free survival 31.6 vs 20.8 months (HR 0.63); pathological complete response 24.0% vs 2.2%[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) |\n| TASUKI-52 (with bevacizumab) | Median OS 30.8 vs 24.7 months (HR 0.74); median PFS 12.1 vs 8.1 months; ORR 61.5% vs 50.5%[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501244/) |\n| PD-L1 selection | Benefit observed across PD-L1 expression levels, including PD-L1-negative patients[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501244/) |\n| Paclitaxel premedication | Chlorphenamine 10 mg IV and dexamethasone 16–20 mg IV 30 minutes before each paclitaxel infusion[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf) |\n| Grade 3/4 toxicity (neoadjuvant) | 33.5% with nivolumab plus chemotherapy vs 36.9% with chemotherapy alone at 68.4 months; most commonly neutropenia[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) |\n\n## How it works\n\nWhen the combination was designed, chemotherapy was hypothesized to augment the effects of immune checkpoint inhibitors, potentially increasing antitumor activity and survival.[6](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01256/full)\n\nIndirect support comes from meta-analyses of nab-paclitaxel (albumin-bound paclitaxel) plus immune checkpoint inhibitors. Across 24 randomized trials enrolling 6,682 patients in five tumor types, the combination improved overall survival (HR 0.79; 95% CI 0.73–0.84), progression-free survival (HR 0.63; 95% CI 0.58–0.69), and pathological complete response (RR 1.28; 95% CI 1.15–1.43) versus controls.[7](https://tcr.amegroups.org/article/view/120219) A second meta-analysis of PD-1/PD-L1 inhibitors with nab-paclitaxel/platinum in NSCLC reported ORR OR 1.81, PFS HR 0.65, and OS HR 0.81 versus chemotherapy alone.[8](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649777/full)\n\nThe paclitaxel formulation matters for immunotherapy. Solvent-based paclitaxel requires polyethoxylated castor oil as a vehicle, which causes hypersensitivity reactions and mandates corticosteroid premedication; nab-paclitaxel avoids this vehicle.[8](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649777/full) Authors of the phase I nivolumab study noted that [nab-paclitaxel regimens](https://www.edgepedia.org/nab-paclitaxel-regimen) offer a theoretical benefit because they avoid corticosteroid premedication and the potential for steroid-induced immune suppression.[6](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01256/full)\n\n## How it is done\n\nIn the neoadjuvant CheckMate 816 regimen, all three drugs are given on day 1 of each 21-day cycle for up to 3 cycles before surgery: nivolumab 360 mg IV, paclitaxel 200 mg/m² IV, and carboplatin AUC 6 IV.[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) Institutional protocols differ on the chemotherapy doses: the UK SWAG Cancer Alliance guide (March 2025) specifies paclitaxel 175 mg/m² with carboplatin AUC 5[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf), while Cancer Care Ontario lists paclitaxel 175–200 mg/m² with carboplatin AUC 5–6.[9](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/71631) [Carboplatin](https://www.edgepedia.org/carboplatin) is dosed with the Calvert equation, \\( \\text{dose (mg)} = \\mathrm{AUC} \\times (\\mathrm{CrCl} + 25) \\)[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf); BC Cancer writes the same formula with GFR.[10](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lung/LUNANIVPC_Protocol.pdf)\n\nNivolumab route varies by protocol: eviQ and Cancer Care Ontario give it intravenously (360 mg, or 4.5 mg/kg to a 360 mg maximum)[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) • [9](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/71631), while BC Cancer permits either 900 mg subcutaneously over 3–5 minutes or 4.5 mg/kg intravenously, with the 360 mg maximum applying only to the weight-based dose.[10](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lung/LUNANIVPC_Protocol.pdf) Patient information confirms all three drugs are given every three weeks as one cycle, with nivolumab available subcutaneously.[11](https://assets.ctfassets.net/u7vsjnoopqo5/4dbcgP0QJLBDKebfuosDIl/15640b26bf8191f5778b24a90b189749/Lung_Carboplatin__Paclitaxel_and_Nivolumab.pdf)\n\nPaclitaxel premedication 30 minutes before infusion is [chlorphenamine](https://www.edgepedia.org/chlorphenamine) 10 mg IV slow bolus and dexamethasone 16–20 mg IV slow bolus; paclitaxel runs in 250–500 mL sodium chloride 0.9% in a non-PVC bag with a 0.22 micron in-line filter over 3 hours.[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf) Supportive care includes count-based delays (treatment delayed for neutrophils < 1.0 × 10⁹/L or platelets < 100 × 10⁹/L), G-CSF for all future cycles after neutropenia, and stepwise dose reductions to paclitaxel 150 mg/m² with carboplatin AUC 4, then 100 mg/m² with AUC 3.[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf)\n\n## Origin\n\nThe combination entered clinical testing in CheckMate 012 (NCT01454102), a phase I trial evaluating nivolumab (BMS-936558) in combination with carboplatin/paclitaxel among other chemotherapy doublets in stage IIIB/IV NSCLC.[12](https://www.clinicaltrials.gov/ct2/show/NCT01454102) A separate multicenter phase I study combined nivolumab with nab-paclitaxel and carboplatin, dosing nab-paclitaxel 100 mg/m² on days 1, 8, and 15 with carboplatin AUC 6 on day 1 every 21 days for 4 cycles, and nivolumab 5 mg/kg IV on day 15 beginning in cycle 1 (concurrent) or cycle 3 (delayed).[6](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01256/full) Interim results showed a best overall response rate of 50% by RECIST v1.1 with median PFS of 10.5 months and no pneumonitis reported.[13](https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.9095)\n\nThe pivotal phase III trials followed: CheckMate 816 in the neoadjuvant resectable setting[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) and TASUKI-52 first-line in metastatic nonsquamous NSCLC.[3](https://pubmed.ncbi.nlm.nih.gov/34139272/)\n\n## Variants\n\nA closely related quadruplet adds bevacizumab. In the metastatic TASUKI-52 regimen, nivolumab or placebo was added to carboplatin, paclitaxel, and bevacizumab every 3 weeks for up to six cycles, followed by maintenance.[3](https://pubmed.ncbi.nlm.nih.gov/34139272/)\n\nA further variant adds ipilimumab to carboplatin and paclitaxel with nivolumab for metastatic disease in the CheckMate 9LA framework.[4](https://www.eviq.org.au/getmedia/798f6494-62d4-4651-af0a-62a00f167d1d/ID-3955-Non-small-cell-cancer-metastatic-cARBOplatin-paclitaxel-ipilimumab-and-nivolumab-protocol-and-PI.pdf.aspx)\n\n## Applications\n\nThe best-established application is neoadjuvant treatment of resectable stage IIA–IIIB (TNM 8th edition) squamous or nonsquamous NSCLC without targetable EGFR or ALK alterations, in patients with ECOG performance status 0–1.[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) In CheckMate 816, median event-free survival was 31.6 months (95% CI 30.2 to not reached) versus 20.8 months (95% CI 14.0 to 26.7) with chemotherapy alone (HR 0.63; 97.38% CI 0.43–0.91; p = 0.005), and pathological complete response was 24.0% versus 2.2% (odds ratio 13.94; p < 0.001).[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) Event-free survival favored the combination in stage IIIA disease, the PD-L1 ≥1% subgroup, and nonsquamous histology.[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and)\n\nIn TASUKI-52, 550 treatment-naïve patients with stage IIIB/IV or recurrent nonsquamous NSCLC without sensitizing EGFR, ALK, or ROS1 alterations, from Japan, Korea, and Taiwan, were randomized 1:1 between June 2017 and July 2019.[3](https://pubmed.ncbi.nlm.nih.gov/34139272/) At the interim analysis (median follow-up 13.7 months), IRRC-assessed median PFS was 12.1 versus 8.1 months (HR 0.56; 96.4% CI 0.43–0.71; P < 0.0001) and objective response rates were 61.5% versus 50.5%.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501244/) Updated analysis with a minimum 19.4 months follow-up showed median OS of 30.8 versus 24.7 months (HR 0.74; 95% CI 0.58–0.94).[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501244/) Benefit was observed across PD-L1 expression levels, including PD-L1-negative patients.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501244/)\n\nLonger CheckMate 816 follow-up showed 4-year overall survival of 71% with nivolumab plus chemotherapy versus 58% with chemotherapy alone, although median OS was not reached in either group and the p value (0.008) did not cross the statistical significance boundary of 0.0033 at latest reporting (HR 0.57; 99.67% CI 0.30–1.07).[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf) • [1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and)\n\n## Limitations and alternatives\n\nAt 68.4 months of CheckMate 816 follow-up, grade 3/4 treatment-related adverse events occurred in 33.5% of the nivolumab plus chemotherapy group versus 36.9% with chemotherapy alone, most commonly neutropenia (8.5% vs 11.9%); no new safety signals were observed.[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) Immune-related adverse events require separate attention from chemotherapy toxicities: they can escalate quickly and close monitoring is required.[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) [Management](https://www.edgepedia.org/management) may require treatment delay and corticosteroids, with an initial dose of 1–2 mg/kg/day prednisolone or equivalent followed by a taper.[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf) [Meta-analysis](https://www.edgepedia.org/meta-analysis) found the combination increased the risk of grade ≥3 thrombocytopenia (RR 1.83) and immune-related adverse events (RR 2.49) versus chemotherapy alone.[8](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649777/full)\n\n A meta-analysis describes the survival benefit of nab-paclitaxel plus checkpoint inhibition as comparable to pembrolizumab plus pemetrexed/platinum in KEYNOTE-189, and notes IMpower132 reported median PFS of 7.0 months with atezolizumab plus nab-paclitaxel/carboplatin versus 5.7 months with chemotherapy alone.[8](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649777/full) The ASCO 2026 guideline for stage IV NSCLC without driver alterations lists atezolizumab + carboplatin + (nab)-paclitaxel with or without bevacizumab, nivolumab + ipilimumab, and nivolumab + ipilimumab + 2 cycles of platinum-based chemotherapy among options regardless of PD-L1 expression; the nivolumab + carboplatin + paclitaxel triplet is not among the listed metastatic options.[14](https://reference.medscape.com/cc2/p10/asco-guideline-stage-iv-nsclc-without-driver-2026a10002j0) For nonsquamous NSCLC with PD-L1 TPS <1%, that guideline recommends pembrolizumab or cemiplimab + carboplatin + pemetrexed and atezolizumab + carboplatin + (nab)-paclitaxel ± bevacizumab.[14](https://reference.medscape.com/cc2/p10/asco-guideline-stage-iv-nsclc-without-driver-2026a10002j0)\n\nTwo dosing questions remain unresolved across protocols: the neoadjuvant paclitaxel dose and carboplatin AUC (200 mg/m² with AUC 6 in eviQ[1](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and) versus 175 mg/m² with AUC 5 in the SWAG guide[5](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf)), and the nivolumab route (IV versus a 900 mg subcutaneous option[10](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lung/LUNANIVPC_Protocol.pdf)). Whether steroid premedication for paclitaxel hypersensitivity blunts immunotherapy efficacy is supported only by the theoretical note that nab-paclitaxel avoids corticosteroid premedication[6](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01256/full); no direct evidence quantifies this interaction, and no published source directly demonstrates immune-priming synergy for this specific triplet.\n\n## References\n\n1. [4318-NSCLC neoadjuvant cARBOplatin PACLitaxel and nivolumab | eviQ](https://www.eviq.org.au/medical-oncology/respiratory/non-small-cell-lung-cancer-adjuvant-neoadjuvant/4318-nsclc-neoadjuvant-carboplatin-paclitaxel-and)\n2. [First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous NSCLC: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC10501244/)\n3. [Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer (ONO-4538-52/TASUKI-52)](https://pubmed.ncbi.nlm.nih.gov/34139272/)\n4. [eviQ protocol 3955: metastatic NSCLC carboplatin, paclitaxel, ipilimumab and nivolumab (CheckMate 9LA)](https://www.eviq.org.au/getmedia/798f6494-62d4-4651-af0a-62a00f167d1d/ID-3955-Non-small-cell-cancer-metastatic-cARBOplatin-paclitaxel-ipilimumab-and-nivolumab-protocol-and-PI.pdf.aspx)\n5. [Quick Reference Guide - Nivolumab, Paclitaxel, Platinum (SW Wales/SWAG Cancer Alliance, 2025)](https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2025/03/Nivo-Paclitaxel-Platinum-v1.pdf)\n6. [Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01256/full)\n7. [Efficacy of nab-paclitaxel combined with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis of randomized controlled trials (Translational Cancer Research)](https://tcr.amegroups.org/article/view/120219)\n8. [Synergistic efficacy and safety of PD-1/PD-L1 inhibitors combined with nab-paclitaxel and platinum chemotherapy in NSCLC: A systematic review and meta-analysis of randomized controlled trials](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649777/full)\n9. [Cancer Care Ontario drug formulary regimen monograph: neoadjuvant nivolumab/carboplatin/paclitaxel](https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/71631)\n10. [BC Cancer Protocol Summary for Neoadjuvant Treatment of NSCLC with Nivolumab, CARBOplatin and PACLitaxel](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lung/LUNANIVPC_Protocol.pdf)\n11. [Carboplatin, Paclitaxel and Nivolumab (patient information)](https://assets.ctfassets.net/u7vsjnoopqo5/4dbcgP0QJLBDKebfuosDIl/15640b26bf8191f5778b24a90b189749/Lung_Carboplatin__Paclitaxel_and_Nivolumab.pdf)\n12. [Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)](https://www.clinicaltrials.gov/ct2/show/NCT01454102)\n13. [Nivolumab + nab-paclitaxel + carboplatin in NSCLC: Interim results from a multicenter phase I study (JCO abstract)](https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.9095)\n14. [Lung Cancer, Non-small Cell Without Driver Alterations: ASCO 2026 Guideline Summary](https://reference.medscape.com/cc2/p10/asco-guideline-stage-iv-nsclc-without-driver-2026a10002j0)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens › Immunotherapy and immunochemotherapy*\n\n*Initially written Sep 29, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/carboplatin-paclitaxel-and-nivolumab-regimen", "markdown_url": "https://www.edgepedia.org/carboplatin-paclitaxel-and-nivolumab-regimen.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Carboplatin, paclitaxel, and nivolumab regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/carboplatin-paclitaxel-and-nivolumab-regimen. Edgepedia Community License 1.0.", "credit_md": "\"[Carboplatin, paclitaxel, and nivolumab regimen](https://www.edgepedia.org/carboplatin-paclitaxel-and-nivolumab-regimen)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/carboplatin-paclitaxel-and-nivolumab-regimen](https://www.edgepedia.org/carboplatin-paclitaxel-and-nivolumab-regimen). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Carboplatin, paclitaxel, and nivolumab regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/carboplatin-paclitaxel-and-nivolumab-regimen. Edgepedia Community License 1.0.", "speakable": "The carboplatin, paclitaxel, and nivolumab regimen combines two chemotherapy drugs with the checkpoint inhibitor nivolumab, given intravenously, and is best established as neoadjuvant treatment of resectable non-small cell lung cancer." }